Aclarion Expands CLARITY Trial Criteria to Boost Enrollment…

Event summary

Aclarion has broadened the enrollment criteria for its CLARITY trial, approved at 9 of 11 active sites, to accelerate patient recruitment.
The revised criteria aim to better reflect real-world chronic low back pain patients while maintaining scientific rigor.
The company expects to provide an updated timeline for the initial readout by year-end, with enrollment expected to accelerate significantly.
Overall trial duration remains on track despite the initial slowdown caused by IRB approval processes.

The big picture

Aclarion's adjustment to the CLARITY trial criteria highlights the challenge of balancing scientific rigor with practical patient recruitment in chronic low back pain studies. The move reflects a strategic pivot to align the trial more closely with real-world clinical practices, which could strengthen the commercial viability of its Nociscan platform. The healthcare technology sector continues to grapple with the need for robust clinical evidence to support innovative diagnostic tools, particularly in areas with high unmet medical needs.

What we're watching

Enrollment Acceleration: Whether the revised criteria will lead to a meaningful increase in enrollment rates across all sites.
Trial Timing: How the updated enrollment pace will impact the initial readout timing and overall trial completion.
Real-World Applicability: The extent to which the expanded criteria will enhance the representativeness of the study population and the real-world applicability of the results.